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INTRODUCTION: Hepatocellular carcinoma (HCC) can develop among chronic hepatitis B patients after hepatitis B
surface antigen (HBsAg) seroclearance. However, whether HCC risk after HBsAg seroclearance differs
between antiviral therapy (AVT)-induced or spontaneous seroclearance cases and ways to identify at-
risk populations remain unclear.
METHODS: A retrospective cohort of 1,200 adult chronic hepatitis B patients who achieved HBsAg seroclearance
(median age: 56 years; 824 men; 165 with cirrhosis; 216 AVT-induced cases) were analyzed. The risk
of HCC after HBsAg seroclearance and the performance of 6 HCC prediction models were assessed.
RESULTS: During amedian of 4.8 years of follow-up (range: 0.5–17.8 years), HCCdeveloped in 23 patients (1.9%).
TheHCC incidence ratewashigher in theAVT-inducedcases than that in the spontaneous cases (3.9%vs
0.9% at 5 years). AVT and cirrhosis were independent factors associated with HCC, with HCC incidence
rates of 0.5%, 1.2%, 4.0%, and 10.5% at 5 years for spontaneous/no-cirrhosis, AVT-induced/no-
cirrhosis, spontaneous/cirrhosis, and AVT-induced/cirrhosis patients, respectively. Among the 6
predictive HCC models tested, Chinese University-HCC score (0.82) showed the highest C-statistics,
which was followed by guide with age, gender, HBV DNA, core promoter mutations and cirrhosis (0.81).
DISCUSSION: AVT-induced HBsAg seroclearance was associated with higher HCC risk, especially for patients with
cirrhosis, indicating that they need careful monitoring for HCC risk. The HCC risk models were able to
stratify the HCC risk in patients with HBsAg seroclearance.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection, defined as the per-
sistence of serum hepatitis B surface antigen (HBsAg) for more
than 6 months, is a major cause of liver cirrhosis and hepato-
cellular carcinoma (HCC) worldwide (1,2). During the natural
course of chronic HBV infection, some patients show the spon-
taneous loss or clearance of HBsAg (3–5). The risk of disease
progression is very low among chronic hepatitis B (CHB) patients
with spontaneous HBsAg seroclearance (6,7) and is considered a
state of functional cure (4). HBsAg seroclearance also occurs in
CHB patients who received or are receiving antiviral therapy
(AVT) (8,9). AVT-induced HBsAg seroclearance is known to be
as durable as spontaneous HBsAg seroclearance (10) and is also
associated with favorable clinical outcomes (8,11). Therefore,
HBsAg seroclearance is considered the ideal endpoint of AVT in
HBV guidelines (3,4). However, it is also known that some CHB
patients with HBsAg seroclearance still develop HCC (12).
To date, limited information is available to indicate whether
AVT-induced HBsAg seroclearance shows the same favorable
clinical outcome as spontaneously inducedHBsAg seroclearance.
In a recent systemic review of 28 studies involving 8,904 CHB
patients with HBsAg seroclearance, the incidence of HCC was
very low (1.86%), and the risk factors of HCC included cirrhosis,
male sex, and age at HBsAg seroclearance (13). However, limited
information is available whether the risk of HCC is comparable
between patients with AVT-induced and spontaneous-induced
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HBsAg seroclearance. In addition, because the HCC incidence
rate after HBsAg seroclearance is low, risk stratification is needed
to guide future follow-up plans, especially regarding HCC sur-
veillance. Yet, there is limited information on the ways to stratify
the HCC risk in CHB patients who have achieved HBsAg sero-
clearance. In this study, we compared the HCC risk between
AVT-induced and spontaneously induced HBsAg seroclearance
to determine whether AVT-induced HBsAg seroclearance was as
safe as spontaneously induced HBsAg seroclearance. We also
assessed the performance of several HCC prediction scores de-
veloped for CHB patients to determine whether these HCC risk
scores could be applied to patients with HBsAg seroclearance.
METHODS
Study design, setting, and participants
This studywas a hospital-based, retrospective,multicenter cohort
study performed at 3 academic institutions in South Korea. The
electronicmedical recordswere screened for patients to include in
the study. We included a total of 1,273 adults aged 18 years or
older who met all inclusion criteria between January 1, 2000 and
December 31, 2016 from each site. The inclusion criteria were as
follows: (i) chronic HBV infection, defined by the presence of
serum HBsAg for more than 6 months; (ii) no coinfection with
hepatitis C virus or HIV; (iii) no history of cancer, including
HCC; (iv) no history of liver transplantation or other solid organ
transplantation, and (v) patients with documented HBsAg loss.
Among them, we excluded 73 patients who met the following
exclusion criteria: (i) 1 patient developedHCCwithin 6months of
HBsAg loss and (ii) 72 patients with follow-up durations less than
6 months from HBsAg loss. Finally, 1,200 chronic HBV mono-
infected patients with documented HBsAg loss, without malig-
nancy or transplantation at baseline, and with more than 6
months of follow-up after HBsAg loss were analyzed in this study
(Figure 1). The study protocol was reviewed and approved by the
Institutional Review Board of each participating site. The re-
quirement for informed consent from the patients was waived
because only deidentified data routinely collected during hospital
visits were used.
Study outcomes, variables, and measurements
The primary outcome was incident HCC during follow-up. HCC
was diagnosed according to the regional HCC diagnostic guide-
lines during the study period (14,15). In brief, HCC was di-
agnosed either by pathology or clinical criteria showing typical
features ofHCC in imaging studies. The index date was defined as
the first date of documented HBsAg loss. The patients were fol-
lowed up from the index visit to the date of the diagnosis of HCC
or to the last clinic visit (reference date: December 31, 2019).
The variables collected were age, sex, and serum alanine
aminotransferase (ALT), aspartate aminotransferase (AST), al-
bumin, bilirubin, and platelet levels measured closest to the index
date. Imaging findings on ultrasonography, computed tomogra-
phy ormagnetic resonance imaging, and information onAVTuse
(interferon, pegylated interferon, lamivudine, adefovir, telbivu-
dine, clevudine, entecavir, and tenofovir) were also collected.
AVT was defined for patients with a history or current use of
AVT at HBsAg loss. Liver cirrhosis was defined by radiological
evaluation when imaging findings suggestive of cirrhosis, a
blunted, nodular liver edge, and/or splenomegaly (16) were
identified. For 53 patients (0.4%), imaging studies within a year of
the index visit were missing. For them, the fibrosis (FIB)-4 index
(age in years 3 AST level in U/L)/([platelet count 3 109/L] 3
[ALT level in U/L]) was calculated and was used to define cir-
rhosis (because cirrhosis was defined when the FIB-4 index was
.3.25) (17,18). Elevated ALT levels were defined as ALT.34 in
men or .30 in women (19). In addition, we also calculated the
Figure 1. Study participants. A total of 1,200 patients were analyzed in this
study. CHB, chronic hepatitis B; HBsAg, hepatitis B surface antigen; HCC,
hepatocellular carcinoma; HCV, hepatitis C virus.
Table 1. Baseline characteristics of patients
All (n 5 1,200) Spontaneous (n 5 984) AVT-induced (n5 216) P HCC (1) (n5 23) HCC (2) (n5 1,177) P
Age, yr 56 (50–62) 57 (51–63) 52 (45–58) ,0.001 58 (55–63) 56 (50–62) 0.23
Men 824 (68.7%) 662 (67.3%) 162 (75.0%) 0.029 20 (87.0%) 804 (68.3%) 0.068
Liver cirrhosis 165 (13.8%) 107 (10.9%) 58 (26.9%) ,0.001 14 (60.9%) 151 (12.8%) ,0.001
AST, U/L 22 (19–27) 22 (19–27) 22 (18–26) 0.07 26 (22–36) 22 (19–27) 0.005
ALT, U/L 20 (15–28) 20 (15–27) 20 (14–28) 0.28 27 (20–34) 20 (15–27) 0.002
Albumin, g/dL 4.5 (4.3–4.6) 4.4 (4.3–4.6) 4.5 (4.3–4.7) 0.020 4.5 (4.1–4.6) 4.5 (4.3–4.6) 0.90
Bilirubin, mg/dL 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.77 0.9 (0.7–1.3) 0.8 (0.6–1.1) 0.22
Platelet count, 103/mL 193 (158–229) 195 (160–231) 180 (143–220) ,0.001 153 (132–217) 193 (159–230) 0.019
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVT, antiviral therapy; HCC, hepatocellular carcinoma.





AST-to-platelet ratio index (20) and the risk estimation for
hepatocellular carcinoma in chronic hepatitis B (REACH-B) (21),
guide with age, gender, HBVDNA, core promoter mutations and
cirrhosis (GAG-HCC) (22), Chinese University-HCC (CU-
HCC) (23), platelets, age, gender hepatitis B (PAGE-B) (24),
modified PAGE-B (25), and age-male-ALBI-platelets (aMAP)
(26) scores using baseline variables.
Statistical analysis
Descriptive statistics for the continuous variables and the cat-
egorical variables are presented by median (interquartile range)
and frequency (%), respectively. Cox regression models were
used to identify the factors associated with incident HCC. AVT,
age, sex, liver cirrhosis, and serumAST, ALT, albumin, bilirubin
levels, and platelet counts were tested in univariable analysis for
HCC development. We included the variables with P values
,0.1 on univariable analysis in amultivariable analysis. Agewas
included in the multivariable analysis, regardless of the P value
on univariable analysis. The cumulativeHCC incidence rate was
estimated using a Kaplan-Meier method, and differences be-
tween the groups were compared with the log-rank test.
To assess the prognostic performance of the HCC pre-
diction models in patients with HBsAg loss, the area under the
receiver operating characteristic curves (AUROCs) was cal-
culated to predict HCC development at 3 and 5 years, re-
spectively. After calculating the AUROC, one with the highest
C-index was used as a reference to test performance of other
model. AUROC was compared with test statistical difference
between models with the cutoff P value of 0.05. Comparison
was performed using the open source statistics software R
(version 3.5.1) in conjunction with pROC package (27) that
used Delong method (28).
RESULTS
Baseline characteristics
The baseline characteristics at HBsAg loss are summarized in
Table 1. The median patient age was 56 years, 68.7% were men,
and 13.8% of the analyzed patients had cirrhosis. Of 1,200 pa-
tients, 984 patients (82%) were spontaneously induced cases,
whereas 216 patients (18%) were AVT-induced cases. Among the
216 AVT-induced cases, the types of AVT used were nucleoside
or nucleotide analogs, interferon/pegylated interferon, and both
nucleoside or nucleotide analogs and interferon/pegylated in-
terferon for 186 (86.1%), 10 (4.6%), and 17 (7.9%) patients,
respectively.
When compared, the AVT-induced cases were younger,
comprised more men, had cirrhosis, and showed higher albumin
levels and lower platelet counts than those of spontaneous-
induced cases (Table 1). When compared between those who
developed and those who did not, those who developed HCC
comprisedmore cirrhosis and showed higher AST andALT levels
and lower platelet count (Table 1).
Incidence and risk factors of HCC
During amedian of 4.8 years of follow-up (range: 0.5–17.8 years),
HCC developed in 23 patients (1.9%). The cumulative incidence
rate of HCC was 1.0%, 1.4%, and 3.2% at 3, 5, and 7 years, re-
spectively. The HCC incidence according to baseline character-
istics is summarized in Table 2. TheHCC incidence was lower for
young adults, women, those without cirrhosis, and those with low
FIB-4 or AST-to-platelet ratio index scores. No significant dif-
ference was found according to baseline ALT levels. In the mul-
tivariable adjusted analysis, AVT (hazard ratio 5 3.10, 95%
confidence interval: 1.26–7.65) and cirrhosis (hazard ratio5 6.23,
95% confidence interval: 2.37–16.40) were independent factors
associated with HCC (Table 3). When stratified according to
cirrhosis andAVTuse, the 5-year cumulativeHCC incidence rate
was 0.5%, 1.2%, 4.0%, and 10.5% for patients without cirrhosis/
spontaneous cases (n 5 877), patients without cirrhosis/AVT-
induced cases (n 5 158), patients with cirrhosis/spontaneous
cases (n 5 107), and patients with cirrhosis/AVT-induced cases
(n 5 58), respectively (Figure 2, P , 0.001).
Role of HCC prediction models for patients with HBsAg loss
The performance of the HCC prediction models for predicting
HCC development at 5 years is summarized in Table 4. Notably,
HBV DNA levels, which contribute to the CU-HCC, GAG-







,50 298 1 0.0 0.0 0.9
50–59 520 12 1.5 2.0 3.1
$60 422 10 1.0 1.5 4.8
Sex 0.07
Women 376 3 0.6 0.9 0.9
Men 824 20 1.2 1.6 4.1
Cirrhosisa ,0.001
No 1,035 9 0.4 0.6 1.6
Yes 165 14 4.6 6.5 13.3
ALT levels 0.35
Normal 1,015 18 1.0 1.3 2.9
Elevatedb 185 5 1.2 1.9 5.0
FIB-4 0.02
,1.45 603 9 0.4 0.9 3
1.45–3.25 525 10 1.4 1.4 2.5
.3.25 75 4 3.4 5.3 9.6
APRI ,0.001
,1 1,162 19 0.8 1.1 1.9
$1 38 4 6.7 10.4 19.4
AVT ,0.001
No 984 12 0.7 0.9 2.2
Yes 216 11 2.5 3.9 8.1
aCirrhosis was defined by radiologic evaluation for 1,147 patients and by
elevated FIB-4 score (.3.25) for 53 patients.
bElevated ALT levels were defined as ALT .34 in men or .30 in women.
ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet
ratio index; AVT, antiviral therapy; FIB-4, fibrosis 4; HCC, hepatocellular
carcinoma.




Risk and Risk Score Performance of HCC 3
HCC, and REACH-B scores, did not contribute to participants
with HBsAg loss. Of the 6 models tested, CU-HCC scores
showed the highest AUROC in the overall population, which
was better than the REACH-B or PAGE-B scores. The GAG-
HCC scores showed the highest AUROC in the spontaneously
induced cases, and the CU-HCC scores showed the highest
AUROC in the AVT-induced cases.
The HCC incidence according to risk scores cutoffs is sum-
marized in Table 5. The HCC incidence was high for those with
medium or high CU-HCC scores (5.3% or 14.3% at 5 years,
respectively) and those with high GAG-HCC scores (7.9% at 5
years), but the HCC risk was not null for those with low CU-
HCC scores (0.6% at 5 years) and those with low GAG-HCC
scores (0.8% at 5 years). By contrast, the HCC incidence rate was
not high even for high PAGE-B scores (2.1% at 5 years) and high
modified PAGE-B scores (2.8% at 5 years), but no HCC de-
veloped in patients with low PAGE-B scores (0% at 5 years), low
modified PAGE-B scores (0% at 5 years), or low aMAP score
(0% at 5 years). When stratified according to AVT use, the HCC
incidence rate was higher for AVT-induced cases compared
with that of spontaneously induced cases, within the same cat-
egory of risk scores (Table 5).
DISCUSSION
In this study, the incidence of HCC among patients with HBsAg
seroclearance was low (1.9%), with a cumulative HCC incidence
rate of 1.4% at 5 years, during a median follow-up duration of 4.8
years. The patients with AVT-induced seroclearance patients
showed a higher risk of HCC compared with the patients with
spontaneously induced seroclearance andwas an independent risk
factor associated with HCC, along with cirrhosis. CU-HCC and
GAG-HCC scores, which include cirrhosis as a variable, showed
better performance than REACH-B, PAGE-B, modified PAGE-B,
or aMAP scores.When the patients were grouped according to the
proposed cutoff values, CU-HCC and GAG-HCC showed higher
performance in identifying the high-risk group, whereas PAGE-B,
modified PAGE-B, and aMAP scores were able to identify patients
who were at null risk of developing HCC within 5 years.
In this study, cirrhosis was an independent factor associated
with HCC development. Similarly, several studies, including a
meta-analysis, have identified the presence of cirrhosis as a key
factor associated with future HCC risk in patients with HBsAg
seroclearance (12,13,29). Male sex and age at HBsAg seroclearance
were also suggested as important risk factors of HCC (29,30). Al-
though age and sex were not independent risk factors in this study,
the HCC incidence rate was higher in men compared with that in
women and was higher for older patients in this study (Table 2).
Notably, the HCC risk was higher for patients with AVT-induced
HBsAg seroclearance than that for patients with spontaneously
induced (0.9% and 3.9% at 5 years, respectively). AVT is usually
considered for patients with persistent inflammation (3–5). Hence,
the AVT-induced group might have experienced prolonged in-
flammation in the liver before HBsAg seroclearance than that by
the spontaneous group. Indeed, when the baseline characteristics
were compared, the prevalence of cirrhosis was higher in the AVT-
induced group (Table 1). HBVDNApersists in the liver andmight
show very-low-level HBV replication after HBsAg seroclearance
(31). Those who achieved spontaneous HBsAg seroclearance
through host immune control might have stronger immune con-
trol of HBV. In a study by Kim et al. (29), the HCC risk was not
higher for patients with AVT-induced HBsAg seroclearance than
that for the spontaneously induced group.However, the number of
AVT-induced cases was relatively small (n 5 105) with shorter
follow-up intervals (median 3.2 years) than that in this study. To
our knowledge, no other studies have directly compared HCC risk
Table 3. Factors associated with hepatocellular carcinoma development
Univariable HR (95% CI) P Multivariable HR (95% CI) P
AVT yes (vs no) 4.97 (2.17–11.4) ,0.001 3.10 (1.26–7.65) 0.014
Age (per year) 1.03 (0.98–1.07) 0.24 1.03 (0.99–1.09) 0.14
Men (vs women) 2.88 (0.85–9.68) 0.09 2.39 (0.69–8.24) 0.17
Cirrhosis (vs no) 10.5 (4.51–24.3) ,0.001 6.23 (2.37–16.40) ,0.001
AST, U/L 1.00 (0.99–1.01) 0.19
ALT, U/L 1.00 (1.00–1.01) 0.28
Albumin, g/dL 0.55 (0.18–1.64) 0.28
Bilirubin, mg/dL 1.65 (0.92–2.94) 0.09 1.22 (0.56–2.66) 0.61
Platelet count, 103/mL 0.99 (0.98–0.99) 0.003 1.00 (0.99–1.01) 0.71
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVT, antiviral therapy; CI, confidence interval; HR, hazard ratio.
Figure 2. Cumulative incidence of hepatocellular carcinoma according to
cirrhosis and antiviral treatment. AVT, antiviral therapy; HCC, hepatocel-
lular carcinoma; LC, liver cirrhosis.





between AVT-induced cases and spontaneously induced cases.
Further data are needed to validate our observations.However, our
findings indicate that patients with AVT-induced seroclearance
warrant more careful attention to increased HCC risk. In addition,
when stratified according to cirrhosis, the 5-year cumulative HCC
incidence rate was 0.5% and 1.2% for patients with spontaneous-
and AVT-induced seroclearance without cirrhosis and 4.0% and
10.5% for patients with spontaneous- and AVT-induced sero-
clearance with cirrhosis, respectively (Figure 2). This suggests that
the ideal AVT endpoint should be HBsAg seroclearance before
cirrhosis. The clinical benefit of AVT-induced HBsAg seroclear-
ance might be low when cirrhosis is present.
In this study, the risk of HCC was low (1.4% at 5 years). Con-
sistently, the reported HCC incidence rate after HBsAg seroclear-
ance is (0.86%–3.7%) (29,30,32,33). Hence, risk-stratification is
needed to provide individualized care, especially in HCC surveil-
lance. Cirrhosis is a strong risk of HCC in patients with HBsAg
seroclearance (12,13,29) and warrants HCC surveillance after
HBsAg seroclearance. Yet, HCCwas also observed in noncirrhotic
patients indicating cirrhosis alone might not be optimal factor to
identify individual who need HCC surveillance fort HBsAg sero-
clearance. In this study, 6 predictive models for HBV-related HCC
were assessed. Among these models, CU-HCC showed the highest
predictive ability (AUROC 0.82), followed by GAG-HCC (0.81).
Liver cirrhosis was the most important predictor for HCC in
HBsAg seroclearance patients (13). The integral components of
CU-HCC and GAG-HCC include liver cirrhosis, whereas those of
REACH-B, PAGE-B, modified PAGE-B, and aMAP do not. CU-
HCC and GAG-HCC, which include liver cirrhosis as a variable,
showed highest AUROC and observed that HCC risk was high
(14.3%–7.9% at 5 years) for those classified as a high risk group.
However, although the incidence was low, HCC development was
observed for patients classifiedas a low-risk groupbyCU-HCCand
GAG-HCC (0.6%–0.8% at 5 years). For REACH-B, PAGE-B, and
modified PAGE-B score, HCC risk was not very high (0.2%–2.8%
at 5 years) for those classified as a high risk group. However, HCC
risk was null (0% at 5 years) for those classified as a low-risk group
by PAGE-B or modified PAGE-B score. For aMAP scores, HCC
risk was comparably high (6.3% at 5 years) for those classified as a
high-risk group, and HCC risk was null (0% at 5 years) for those
classified as a low-risk group. These different risk models warrant
further validation but might be used as an initial step to identify
high-risk patient who need HCC surveillance (CU-HCC, GAG-
HCC, and aMAP) and to identify very-low-risk patientswhomight
be exempted fromHCC surveillance (PAGE-B,modifiedPAGE-B,
and aMAP).Among risk scores, aMAPscorewas able to triageboth
high- and very-low-risk patients. Notably, the HCC risk was, es-
pecially, higher for patients with AVT-induced seroclearance with
higher scores, indicated by HCC risk models (Table 5).
This study had some limitations. The study had the inherent
limitations of a retrospective cohort study. Because HBsAg was not
systemically evaluated at regular intervals, the age at seroclearance
might be earlier than the date of documentation of HBsAg sero-
clearance in this study. Liver cirrhosis was defined radiologically,
which has interobserver and intraobserver variability and was
assessed bymany radiologists in 3 centers. However, the radiologists
were unaware of the study’s aim, and the direction of bias was
nondifferential. There were 53 patients (0.4%) withmissing imaging
Table 4. Performance of risk prediction models for hepatocellular carcinoma development at 5 years









































































0.06 0.73 (0.53–0.93) 0.08
aP value, comparedwith CU-HCC score. For CU-HCC score, 0 point was given for HBVDNA score. For GAG-HCC score, 0 point was given for HBVDNA andBCPmutation.
For REACH-B score, 0 point was given for HBV DNA and HBeAg.
aMAP, age-male-ALBI-platelets; AUROC, area under the receiver operating characteristic curve; ALT, alanine aminotransferase; AVT, antiviral therapy; BCP, basal core
promoter; CI, confidence interval; CU-HCC, ChineseUniversity-HCC;GAG-HCC, guidewith age, gender,HBVDNA, core promotermutations andcirrhosis; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; PAGE-B, platelets, age, gender hepatitis B; REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B.
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studies within a year of the index visit, in which we used FIB-4 to
define cirrhosis. Hence, more objective measures of fibrosis burden
obtained by liver biopsies or fibroscansmight providemore accurate
information on the futureHCC risk. Therewere several unmeasured
factors, including a family history of HCC, alcohol use, smoking,
metabolic syndrome, fatty liver, and/or steatohepatitis, which might
be associated withHCC development in these patients. The primary
outcome incidence was small (HCC, n 5 23) and had to include
strong alleged risk factors and analyze in the model. Studies with
larger sample sizes withmore events (primary outcome) are needed.
AlthoughHBV genotype studywasmissing for this study, almost all
HBV infections found in SouthKoreawere infectedwith genotypeC
HBV (1). Hence, the generalizability to other ethnicities and patients
infected with other HBV genotypes warrants validation. HCC sur-
veillance requires medical cost and is not harm free. Hence, addi-
tional studies, including cost-effective analysis, are required to find
out optimal surveillance strategy for patients with HBsAg sero-
clearance.The strengthof thesedatawas the large sample size, careful
definition of the study variables, and relatively long follow-upperiod.
In conclusion, we found that HCC risk was generally low after
HBsAg seroclearance but was not null. AVT was an independent
risk factor, along with cirrhosis, and the HCC risk was consid-
erable, especially for cirrhotic patients who achieved HBsAg
seroclearance by AVT. This indicates that AVT-induced HBsAg
seroclearance might not be as safe as spontaneous HBsAg sero-
clearance, especially when cirrhosis is present. The HCC risk
models showed acceptable performance in patients with HBsAg
seroclearance. The CU-HCC and GAG-HCC scores were useful
in identifying high-risk patients, whereas PAGE-B and modified
PAGE-B scores were useful in identifying very-low-risk patients.
These risk scores might be used together to stratify future HCC
risk in patients with HBsAg seroclearance.
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Study Highlights
WHAT IS KNOWN
3 Loss or seroclearance of hepatitis B surface antigen (HBsAg)
can occur spontaneously or by antiviral therapy.
3 Several hepatocellular carcinoma (HCC) risk models are
available to predict HCC risk for chronic hepatitis B patients.
WHAT IS NEW HERE
3 HCC risk was higher in antiviral therapy-induced HBsAg
seroclearance than spontaneous case.
3 HCC riskmodels were able to stratify HCC risk in patients with
HBsAg seroclearance.
TRANSLATIONAL IMPACT
3 Patients with antiviral therapy-induced HBsAg seroclearance
warrants more close attention for HCC risk.
3 HCC risk models can be used to stratify HCC risk in patients
with HBsAg seroclearance.
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